DW1807
/ Daewon Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 12, 2025
Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma
(clinicaltrials.gov)
- P3 | N=274 | Recruiting | Sponsor: Daewon Pharmaceutical Co., Ltd.
New P3 trial • Allergic Rhinitis • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1